Trial reportFrontiers in cellular and infection microbiology2025
Short-term pegylated interferon alpha in chronic HBV patients with ultra-low HBsAg: a retrospective study.
Trial report in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Leveraging machine learning to identify optimal patient populations for PEG-IFN therapy in CHB and constructing nomogram models of interferon response: a 48-week follow-up study.BMC gastroenterology · 2026Article
- Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Hepatitis B surface antigen (HBsAg) clearance-defined as an HBsAg level below the lower limit of detection-is critical for the functional cure of chronic hepatitis B (CHB). This study evaluated the efficacy of short-term pegylated interferon alpha (Peg-IFNα) therapy in achieving HBsAg clearance in CHB patients with ultra-low HBsAg levels (<50 IU/ml). Methods: A total of 378 CHB patients with HBsAg levels <50 IU/ml were enrolled, including 206 nucleos(t)ide analogue (NUC)-treated patients and 172 inactive HBsAg carriers (IHCs). The NUC-treated cohort was divided into 83 patients receiving additional Peg-IFNα treatment (NUC add-on Peg-IFNα group) and 123 patients continuing NUC monotherapy (NUC group). The IHC cohort was divided into 86 patients receiving Peg-IFNα treatment (Peg-IFNα group) and 86 untreated patients (untreated group). The primary endpoint was the HBsAg clearance rate at week 24. Results: At week 24, the HBsAg clearance rates in the NUC add-on Peg-IFNα group and Peg-IFNα group were 69.88% and 55.81%, respectively (p = 0.059), both significantly higher than the zero clearance rates in the NUC and untreated groups (p < 0.001). Patients with baseline HBsAg <10 IU/ml achieved higher clearance rates [81.82% vs. 73.81% (p = 0.144)]. A decline of ≥95.8% in HBsAg levels from baseline to week 12 predicted HBsAg clearance at week 24 (AUC ≥0.9, sensitivity 0.765, specificity 0.961). Conclusions: Short-term Peg-IFNα therapy achieved high and comparable HBsAg clearance rates within 24 weeks in NUC-treated patients and IHCs with ultra-low HBsAg levels. Clinical trial registration: https://www.medicalresearch.org.cn/login, identifier MR-50-24-011565.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.